Jason M. Shohet
  • Department of Pediatrics, Baylor College of Medicine, USA
  • Cancer biology


M.D., Ph.D. in Pathology, Boston University, School of Medicine, 1993

Current position

Associate Professor, Department of Pediatrics, Baylor College of Medicine, Houston, TX (2012- present)


Selected peer-reviewed publications

  1. Barone, G., A Tweddle, D., M Shohet, J., Chesler, L., Moreno, L., DJ Pearson, A. and Van Maerken, T. (2014). MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current drug targets 15(1): 114-123.
  2. Fan, Y., Cheng, J., Vasudevan, S., Dou, J., Zhang, H., Patel, R., Ma, I., Rojas, Y., Zhao, Y. and Yu, Y. (2013). USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell death & disease 4(10): e867.
  3. Ghosh, R., Singh, L. C., Shohet, J. M. and Gunaratne, P. H. (2013). A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 34(3): 807-816.
  4. Barbieri, E., De Preter, K., Capasso, M., Chen, Z., Hsu, D. M., Tonini, G. P., Lefever, S., Hicks, J., Versteeg, R. and Pession, A. (2013). Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma. Cancer research.
  5. Barbieri, E., De Preter, K., Capasso, M., Johansson, P., Man, T.-K., Chen, Z., Stowers, P., Tonini, G. P., Speleman, F. and Shohet, J. M. (2013). A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma. PloS one 8(11): e79843.
  6. Hsu, D. M., Agarwal, S., Benham, A., Coarfa, C., Trahan, D. N., Chen, Z., Stowers, P. N., Courtney, A. N., Lakoma, A. and Barbieri, E. (2013). Expression of the G-CSF receptor, CD114, marks a novel, highly tumorigenic cell population in a neuroblastoma cell line. Cancer Research: canres. 4056.2012.
  7. Patterson, D. M., Shohet, J. M. and Kim, E. S. (2011). Pre-clinical Models of Pediatric Solid Tumors (Neuroblastoma) and their Use in Drug Discovery. Curr Postdoc Pharmacol (52)14.17.1-14.
  8. Shohet, J. M., Ghosh, R., Coarfa, C., Ludwig, A., Benham, A. L., Chen, Z., Patterson, D. M., Barbieri, E., Mestdagh, P. and Sikorski, D. N. (2011). A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer research 71(11): 3841-3851.
  9. Patterson, D. M., Shohet, J. M., Kim, E. S. (2011). Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol. Mar; Chapter 14: Unit 14.17.
  10. Shang, X., Vasudevan, S., Yu, Y., Ge, N., Ludwig, A., Wesson, C., Wang, K., Burlingame, S., Zhao, Y. and Rao, P. (2010). Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene 29(35): 4938-4946.
  11. Chen, Z., Lin, Y., Barbieri, E., Burlingame, S., Hicks, J., Ludwig, A. and Shohet, J. M. (2009). Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia (New York, NY) 11(8): 753.
  12. Wei, J. S., Song, Y. K., Durinck, S., Chen, Q.-R., Cheuk, A. T. C., Tsang, P., Zhang, Q., Thiele, C. J., Slack, A. and Shohet, J. (2008). The MYCN oncogene is a direct target of miR-34a. Oncogene 27(39): 5204-5213.
  13. Honeycutt, K., Chen, Z., Koster, M., Miers, M., Nuchtern, J., Hicks, J., Roop, D. and Shohet, J. (2006). Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene 25(29): 4027-4032.
  14.  Barbieri, E., Mehta, P., Chen, Z., Zhang, L., Slack, A., Berg, S. and Shohet, J. M. (2006). MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Molecular cancer therapeutics 5(9): 2358-2365.
  15.  Slack, A., Chen, Z., Tonelli, R., Pule, M., Hunt, L., Pession, A. and Shohet, J. M. (2005). The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 102(3): 731-736.